MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

NCT05068466 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-16

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded, Phase 1 study designed to evaluate the safety, tolerability, and PK of escalating oral doses of INCB054707 in healthy male Japanese participants. Participants in each cohort will be divided into placebo or INCB054707 by a 3:1 INCB054707:placebo random assignment.

Conditions

  • Healthy Participants

Interventions

DRUG

INCB054707

Administered Orally

DRUG

Placebo

Administered Orally

Sponsors & Collaborators

  • Incyte Biosciences Japan GK

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2022-01-25
Completion
2022-01-25
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05068466 on ClinicalTrials.gov